NYSE:GSK - GlaxoSmithKline Stock Price, Price Target & More

GlaxoSmithKline trades on the New York Stock Exchange (NYSE) under the ticker symbol "GSK."

GlaxoSmithKline declared a quarterly dividend on Thursday, April 26th. Shareholders of record on Friday, May 11th will be paid a dividend of $0.5298 per share on Thursday, July 12th. This represents a $2.12 annualized dividend and a yield of 5.08%. The ex-dividend date is Thursday, May 10th. View GlaxoSmithKline's Dividend History.

GlaxoSmithKline plc (NYSE:GSK) announced its quarterly earnings data on Wednesday, April, 25th. The pharmaceutical company reported $0.68 EPS for the quarter, missing the consensus estimate of $0.70 by $0.02. The pharmaceutical company earned $10.04 billion during the quarter, compared to the consensus estimate of $10.26 billion. GlaxoSmithKline had a return on equity of 144.84% and a net margin of 3.50%. View GlaxoSmithKline's Earnings History.

GlaxoSmithKline is scheduled to release their next quarterly earnings announcement on Wednesday, July, 25th 2018. View Earnings Estimates for GlaxoSmithKline.

13 analysts have issued 1-year price objectives for GlaxoSmithKline's shares. Their forecasts range from $35.85 to $40.00. On average, they expect GlaxoSmithKline's stock price to reach $38.6167 in the next twelve months. This suggests that the stock has a possible downside of 7.5%. View Analyst Ratings for GlaxoSmithKline.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GlaxoSmithKline in the last year. There are currently 8 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold."

GlaxoSmithKline saw a decrease in short interest during the month of May. As of May 31st, there was short interest totalling 8,497,397 shares, a decrease of 27.2% from the May 15th total of 11,675,520 shares. Based on an average trading volume of 2,406,543 shares, the short-interest ratio is presently 3.5 days. View GlaxoSmithKline's Current Options Chain.

Some companies that are related to GlaxoSmithKline include Johnson & Johnson (JNJ), Pfizer (PFE), Novartis (NVS), Merck & Co., Inc. (MRK), AbbVie (ABBV), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT), Sanofi (SNY), Eli Lilly And Co (LLY), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG), Allergan (AGN) and Shire (SHPG).

News stories about GSK stock have trended positive recently, according to Accern Sentiment Analysis. The research group scores the sentiment of news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. GlaxoSmithKline earned a coverage optimism score of 0.33 on Accern's scale. They also gave media coverage about the pharmaceutical company an impact score of 46.26 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

GlaxoSmithKline's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Fisher Asset Management LLC (0.56%), Confluence Investment Management LLC (0.06%), Farmers Trust Co. (0.00%), Fulton Bank N.A. (0.00%), BLB&B Advisors LLC (0.00%) and Bogart Wealth LLC (0.00%). View Institutional Ownership Trends for GlaxoSmithKline.

GSK stock was sold by a variety of institutional investors in the last quarter, including Confluence Investment Management LLC, Farmers Trust Co., Atria Investments LLC, Park National Corp OH, Cullinan Associates Inc., Fulton Bank N.A., Gofen & Glossberg LLC IL and BLB&B Advisors LLC. View Insider Buying and Selling for GlaxoSmithKline.

GSK stock was bought by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, Guardian Investment Management, First Financial Bank Trust Division, First Citizens Bank & Trust Co., TNB Financial, RDL Financial Inc., Bogart Wealth LLC and Community Bank & Trust Waco Texas. View Insider Buying and Selling for GlaxoSmithKline.

Shares of GSK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of GSK stock can currently be purchased for approximately $41.74.

GlaxoSmithKline has a market capitalization of $103.49 billion and generates $38.89 billion in revenue each year. The pharmaceutical company earns $1.97 billion in net income (profit) each year or $2.88 on an earnings per share basis. GlaxoSmithKline employs 99,827 workers across the globe.

GlaxoSmithKline's mailing address is 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0, TW8 9GS. The pharmaceutical company can be reached via phone at 44-20-8047-5000 or via email at [email protected]